Mayo Clinic · Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Nat Rev Clin Oncol, Jan 2026Diagnosis, risk stratification and management of smouldering multiple myeloma.
Research view
Multiple myeloma: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- BCMA 134
- CD38 22
- GPRC5D 36
- CD19 31
- TP53 0
- STAT3 0
- CXCR4 4
- MYC 0
- BCL-2 2
- PI3K 1
- mTOR 0
- IL-6 0
- STING 0
- BRAF 2
- CD47 1
- HDAC 0
- AKT 0
- PD-1 1
- PD-L1 1
- CD20 3
- GLP-1 0
- JAK 0
- PTEN 0
- SGLT2 0
- AMPK 0
- B7-H3 0
- NRAS 1
- TIGIT 0
- CTLA-4 1
- ERK 0
- EZH2 0
- FTO 0
- IL-15 3
- JNK 0
- KRAS 1
- MAPK 0
- RAS 0
- CD22 2
- CD33 1
- CTNNB1 0
- EGFR 0
- FGFR 0
- LAG-3 0
- MDM2 0
- METTL3 0
- NRF2 0
- BRCA1 0
- BRD4 0
- BTK 1
- CD123 1
- CD30 0
- CDK4/6 0
- GPX4 0
- HER2 0
- HIF-1 0
- HSP90 0
- MEK 0
- MET 0
- MUC1 0
- NTRK 0
EU-13 is a filter, not a ranking: it only narrows the list.
New York, United States
Boston, United States
Atlanta, United States
Milwaukee, United States
Nantes, France
Hamburg, Germany
Duarte, United States
The University of Texas Southwestern Medical Center · Dallas, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Blood Cancer J, Jan 2026Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.
Heidelberg, Germany
Jacksonville, United States
Kansas City, United States
Miami, United States
University of Pennsylvania · Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Blood Adv, Feb 2026Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma.
Salt Lake City, United States
Paris, France
Tel Aviv, Israel
Ostrava, Czechia
Melbourne, Australia
Poitiers, France
New Haven, United States
Brno, Czechia
Milan, Italy
23 of 23+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 23
- Organoids 3
- Mendelian Randomization Analysis 10
- CRISPR-Cas Systems 8
- Gene Expression Profiling 44
- Sequence Analysis, RNA 7
- Whole Genome Sequencing 4
- Exome Sequencing 3
- Proteomics 15
- Metabolomics 10
- Mass Spectrometry 7
- Flow Cytometry 48
- Immunohistochemistry 11
- Liquid Biopsy 2
- Circulating Tumor DNA 2
- Xenograft Model Antitumor Assays 78
- Positron-Emission Tomography 14
- Magnetic Resonance Imaging 26
- Machine Learning 17
- Deep Learning 6
- Cohort Studies 32
- Genome-Wide Association Study 7
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.